Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Fentanyl[1] Fentanyl[1] Fentanyl 💬[1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[3] 46, 70, 215 💬
2Fentanyl (High Dose)[1] Fentanyl[1] Fentanyl 💬[1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[1] 215 💬
3Fentanyl (Low Dose)[1] Fentanyl[1] Fentanyl 💬[1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[1] 215 💬
4Fentanyl (Low Dose) + Dexmedetomidine[2] Dexmedetomidine,
Fentanyl		[2] Fentanyl ,
Dexmedetomidine 💬		[4] ADRA2A,
ADRA2B,
ADRA2C,
OPRM1 💬		[4] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬[1] 215 💬
5Fentanyl transdermal patch[1] Fentanyl[1] Fentanyl 💬[1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[1] 46 💬
6Multi-modal pain management [Fentanyl][1] Fentanyl[1] Fentanyl 💬[1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[1] 70 💬
7Standard analgesia use [Fentanyl][1] Fentanyl[1] Fentanyl 💬[1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[1] 70 💬
8Transdermal fentanyl matrix, gabapentin[2] Fentanyl,
Gabapentin		[2] Fentanyl ,
Gabapentin 💬		[6] CACNA2D1,
CACNA2D2,
CACNA2D3,
CACNA2D4,
OPRM1,
SLC6A1 💬		[12] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Estrogen signaling pathway, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Synaptic vesicle cycle 💬[1] 70 💬